Neurol. praxi. 2021;22(4):303-307 | DOI: 10.36290/neu.2021.043

Drug-induced depression

doc. MUDr. Dana Končelíková, Ph.D.
Klinika psychiatrie FN a UP, Olomouc

Drug treatment plays a key role in modern medicine. Each use is associated with a number of benefits, but the fact that the patient may be harmed by the treatment cannot be overlooked. The spectrum of effects is as wide as the indication. Among the possible pitfalls of pharmacology include the risk of inducing mental difficulties, eg. a mood disorder. Depressive symptoms or depression itself are described, for example, with the administration of corticoids, antiparkinsonians, antivirals but also commonly used drugs such as beta-blockers, statins or opioid analgesics. It should be added that the development of depressive symptoms is not one of the various side effects of pharmacology and therefore that pharmacogenic induced depression is rare. Listing all potentially hazardous drugs is not possible and the article aims to describe those commonly used and best described.

Keywords: depression, depressive symptoms, corticoids, beta-blockers, statins, opioid analgesics, antiparkinsonian agents, anticonvulsants, interferons.

Received: June 1, 2021; Revised: June 16, 2021; Accepted: June 16, 2021; Prepublished online: June 16, 2021; Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Končelíková D. Drug-induced depression. Neurol. praxi. 2021;22(4):303-307. doi: 10.36290/neu.2021.043.
Download citation

References

  1. Agustini B, Mohebbi M, Woods RL, McNeil JJ, Nelson MR, Shah RC, Murray AM, Ernst ME, Reid CM, Tonkin A. The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: A cross-sectional study. J. Hum. Hypertens. 2020; 34: 787-794. Go to original source... Go to PubMed...
  2. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clinical Pharmacology & Therapeutics 1972; 13(5part1): 694-698. Go to original source... Go to PubMed...
  3. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004; 56: 819-824. Go to original source... Go to PubMed...
  4. Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC. Depressogenic effects of medications: a review. Dialogues in clinical neuroscience 2011; 13(1): 109. Go to original source... Go to PubMed...
  5. Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM. Neuropsychiatric Consequences of Lipophilic Beta-Blockers. Medicina. 2021; 57(2): 155. Go to original source... Go to PubMed...
  6. Čapková Š, Čadová J, Mališ J, Klovrzová S. Terapeutické možnosti u hemangiomů. Dermato. praxi 2013; 7(3): 109-112.
  7. Feinstein A, O'Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression. Journal of neurology 2002; 249(7): 815-820. Go to original source... Go to PubMed...
  8. Fellenius E. Muscle fatigue and beta-blockers - a review. Int. J. Sports Med. 1983; 4: 1-8. Go to original source... Go to PubMed...
  9. Gift AG, Wood RM, Cahill CA. Depression, somatization and steroid use in chronic obstructive pulmonary disease. International journal of nursing studies 1989; 26(3): 281-286. Go to original source... Go to PubMed...
  10. Hou XJ, Xu JH, Wang J, Yu YY. Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One 2013; 8: e76799 Go to original source... Go to PubMed...
  11. Howe CQ, Sullivan, MD. The missing 'P'in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. General hospital psychiatry 2014; 36(1): 99-104. Go to original source... Go to PubMed...
  12. Jaunarajs KLE, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neuroscience & Biobehavioral Reviews 2011 35(3): 556-564. Go to original source... Go to PubMed...
  13. Ji MJ, Yang, J, Gao ZQ, Zhang L, Liu C. The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications. Frontiers in Neuroscience 2021; 15: 130. Go to original source... Go to PubMed...
  14. Jin S, Kostka K, Posada JD, Kim Y, Seo SI, Lee DY, Shah NH, Roh S, Lim YH, Chae SG. Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases. J. Pers. Med. 2020; 10: 288. Go to original source... Go to PubMed...
  15. Khan DA, Brown ES, Suppes P, Carmody TJ. Mood changes during prednisone bursts for asthma. American journal of respirátory and critical care medicine 1999; 159(3): 919.
  16. Kotlyar M, Dysken M, Adson DE. Update on drug-induced depression in the elderly. The American journal of geriatric pharmacotherapy 2005; 3(4): 288-300. Go to original source... Go to PubMed...
  17. Lafay-Chebassier C, Chavant F, Favrelière S, Pizzoglio V, Pérault-Pochat MC. French Association of Regional Pharmacovigilance Centers. Drug-induced Depression: a Case/Non Case Study in the French Pharmacovigilance Database. Therapie 2015; 70(5): 425-32. Go to original source... Go to PubMed...
  18. Lee MC, Peng TR, Lee CH, Wang JY, Lee JA, Chen SM, Shiang, JC. Statin Use and Depression Risk: A Systematic Review and Meta-Analysis. Journal of Affective Disorders. 2021; 282: 308-315. Go to original source... Go to PubMed...
  19. Leutner M, Matzhold C, Kautzky A, Kaleta M, Thurner S, Klimek P, Kautzky-Willer A. Major depressive disorder (MDD) and antidepressant medication are overrepresented in high-dose statin treatment. Frontiers in medicine 2021; 8: 56. Go to original source... Go to PubMed...
  20. Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50(5): 1072-1076. Go to original source... Go to PubMed...
  21. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. British Medical Journal 1990; 301(6747): 309-314. Go to original source... Go to PubMed...
  22. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996; 21(1): 25-31. Go to original source... Go to PubMed...
  23. Parsaik AK, Singh, B, Hassan MM, Singh K, Mascarenhas SS, Williams MD, Rummans TA. Statins use and risk of depression: a systematic review and meta-analysis. Journal of affective disorders 2014; 160: 62-67. Go to original source... Go to PubMed...
  24. Perantie DC, Brown ES. Corticosteroids, immune suppression, and psychosis. Current psychiatry reports 2002; 4(3): 171-176. Go to original source... Go to PubMed...
  25. Pérez-Stable EJ, Halliday R, Gardiner PS, Baron RB, Hauck WW, Acree M, Coates TJ. The effects of propranolol on cognitive function and quality of life: A randomized trial among patients with diastolic hypertension. Am. J. Med. 2000; 108: 359-365. Go to original source... Go to PubMed...
  26. Politis M, Niccolini F. Serotonin in Parkinson's disease. Behavioural brain research 2015; 277: 136-145. Go to original source... Go to PubMed...
  27. Porter RJ, Gallagher P, Watson S, Young AH. Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacology 2004; 173(1): 1-17. Go to original source... Go to PubMed...
  28. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 2005; 66: 41-48. Go to original source... Go to PubMed...
  29. Scherrer JF, Salas J, Copeland LA, Stock EM, Ahmedani, BK, Sullivan MD, Lustman PJ. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. The Annals of Family Medicine, 2016; 14(1): 54-62. Go to original source... Go to PubMed...
  30. Sullivan MD. Why does depression promote long-term opioid use? Pain 2016; 157(11): 2395-2396. Go to original source... Go to PubMed...
  31. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch. Intern. Med. 1990; 150: 2286-2290. Go to original source... Go to PubMed...
  32. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. European journal of epidemiology 2011: 26(1): 1. Go to original source... Go to PubMed...
  33. World Health Organization. MKN-10: Mezinárodní klasifikace nemocí a přidružených zdravotních problémů: desátá revize. Aktualizovaná druhá verze k 1. 4. 2014.
  34. You H, Lu W, Zhao S, Hu Z, Zhang, J. The relationship between statins and depression: a review of the literature. Expert opinion on pharmacotherapy 2013; 14(11): 1467-1476. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.